Secukinumab on Cardiovascular and Renal Endpoints in Cardiorenal Metabolic Syndrome and ASCVD

Phase 4, randomised, open-label trial of secukinumab in Cardiovascular-Kidney-Metabolic Syndrome (CKM) and atherosclerotic cardiovascular disease (ASCVD) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Time to First Occurrence of 3-point Major Adverse Cardiovascular Events up to 2 years. Planned start Jul 2026; status: not yet recruiting.